Search the database for deliberate release of GM medicinal products
Displaying 1 - 4 of 4
|EU record number
|Company / Sponsor
|A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL
|Miltenyi Biotech GmbH
|CD19 and CD20 chimeric antigen receptor
|A phase 2 study to assess the safety and efficacy of GM Lactococcus lactis for the attenuation of oral mucositis in subjects with cancers of the head and neck
|Biologically contained strain of Lactococcus lactis, genetically modified to secrete human Trefoil Factor 1 (hTFF1).
|Only notified under the "contained use" procedure. Dossier submitted on 04/10/2018.
|A Phase 3, Randomized, Double-blind, Placebo-controlled study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1 + Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy
|Replication deficient lentiviral vector encoding NY-ESO-1 cancer testis antigen
|Only notified under the "contained use" procedure. Dossier submitted on 02/01/1996.
|Gene therapy for the treatment of glioblastoma multiforme with in vivo tumor transduction with the herpes simplex thymidine kinase gene /ganciclovir system
|Sandoz Pharma, LTD
|Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)